Anti-PGLYRP1 / PGRP-S Reference Antibody (Novo Nordisk patent anti-PGLYRP1)
Recombinant Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application ![]()
| FC, E, FTA |
---|---|
Primary Accession | O75594 |
Reactivity | Human |
Clonality | Monoclonal |
Isotype | IgG4SP |
Calculated MW | 150 KDa |
Target/Specificity | PGLYRP1 / PGRP-S |
---|---|
Endotoxin | < 0.001EU/ µg,determined by LAL method. |
Conjugation | Unconjugated |
Expression system | CHO Cell |
Format | Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column. |
Name | PGLYRP1 |
---|---|
Synonyms | PGLYRP, PGRP, TNFSF3L |
Function | Innate immunity protein that plays several important functions in antimicrobial and antitumor defense systems. Acts as a pattern receptor that binds to murein peptidoglycans (PGN) of Gram- positive bacteria and thus provides bactericidal activity (PubMed:9707603). Forms an equimolar complex with heat shock protein HSPA1A and induces programmed cell death through apoptosis and necroptosis in tumor cell lines by activating the TNFR1 receptor on the target cell membrane (PubMed:21247889, PubMed:26183779). In addition, acts in complex with the Ca(2+)-binding protein S100A4 as a chemoattractant able to induce lymphocyte movement (PubMed:26654597). Mechanistically, this complex acts as a ligand of the chemotactic receptors CCR5 and CXCR3 which are present on the cells of the immune system (PubMed:30713770). Promotes also the activation of lymphocytes that become able to kill virus-infected cells as well as tumor cells by modulating the spectrum of their target-cell specificity (PubMed:28977785, PubMed:29083508). Induction of cytotoxicity on monocyte surface requires interaction with TREM1 receptor (PubMed:25595774, PubMed:28977785). |
Cellular Location | Secreted. Cytoplasmic granule |
Tissue Location | Highly expressed in bone marrow. Weak expression found in kidney, liver, small intestine, spleen, thymus, peripheral leukocyte, lung, fetal spleen and neutrophils |

Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.

If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.